Genetics and Memory: How APOE, Tau, and Amyloid Shape Cognitive Health in Parkinson’s

When we look at Parkinson’s, we know it is not a "one size fits all" condition. Recent research published in npj Parkinson's Disease on 18 February 2026 has shed new light on why some people experience changes in memory and thinking faster than others. By studying three specific groups—those with sporadic Parkinson’s (no known genetic link), those with the GBA1 variant, and those with the LRRK2 variant—scientists have found that the biological "drivers" of cognitive decline are actually quite different depending on your genetic makeup. The study followed 585 people over several years, looking closely at "biomarkers" in their spinal fluid—specifically Amyloid-beta (Aβ42) and Tau. These are proteins often associated with Alzheimer’s, but we now know they play a massive role in Parkinson’s too. The researchers also looked at the APOE ε4 gene, which is a well-known risk factor for memory loss. What they discovered is a fascinating map of how these different factors interact to change the trajectory of the condition. Different Genes, Different Drivers For those with sporadic Parkinson’s or the GBA1 variant, the presence of the APOE ε4 gene acted like an accelerator for cognitive decline. In these groups, having this specific gene made it much more likely that memory and thinking skills would decrease over time. Interestingly, for people with the LRRK2 variant, the APOE gene did not seem to have the same negative impact, suggesting that the LRRK2 type of Parkinson’s might follow a different biological path entirely. The study also found that low levels of Amyloid-beta in the spinal fluid (a sign that it is clumping in the brain) were a strong predictor of future memory issues across all groups. However, Tau—another protein that causes "tangles" in brain cells—had a much more aggressive impact on those with the GBA1 variant. This suggests that people with GBA1 Parkinson’s may be more sensitive to the combined damage of alpha-synuclein and these Alzheimer’s-related proteins. Why This Matters for Personalised Care This research is a huge step toward "Personalised Medicine." It tells us that we cannot treat every person with Parkinson’s the same way when it comes to protecting brain health. If we know a person’s genetic profile and their biomarker levels, we can start to predict who might need earlier intervention or different types of therapy to support their cognition. For the community, this highlights the vital importance of genetic testing and participation in longitudinal studies. By understanding whether your condition is driven more by amyloid, tau, or genetic variants like GBA1 or LRRK2, we can move closer to clinical trials that are tailored specifically to you. This study proves that while the outward signs of Parkinson’s may look similar, what is happening under the surface is unique to each individual, and our future treatments must reflect that.